High-Throughput Peptide Array Clinical Validation for Lung Adenocarcinoma Detection

Proteins are pivotal in life processes; however, the
constraints
of current detection technologies limit our comprehensive understanding
of their mechanisms. Disease progression, particularly in complex,
multifactorial conditions, such as lung cancer, involves the dysregulation
of numerous proteins. While protein array technology has been at the
forefront in proteomic analysis, its challenges in detection throughput,
sensitivity, specificity, and cost-effectiveness have impeded its
broader clinical application. The enzymatic cleavage of proteins in
the bloodstream into peptides of diverse sizes presents an opportunity
for peptide array technology, providing both a theoretical basis and
practical utility. We have developed a high-throughput peptide array
specifically designed for the diagnosis and treatment of lung adenocarcinoma,
encompassing peptides from 5 to 16 amino acids in length. This array
provides comprehensive coverage of peptides derived from proteins
with high mutation frequencies in lung adenocarcinoma as well as those
that are differentially expressed in association with the disease.
The array’s potential for thorough lung cancer surveillance
is demonstrated through the concurrent detection and classification
of five distinct sample types: healthy controls, benign nodules, stage
I lung adenocarcinoma, and both pre- and postoperative samples.